⚠ Evidence warning: Clinical trials or other evidence do not support the claimed match with droperidol and metoclopramide after surgery, the doses given for food poisoning, stomach flu and hangover, and the children's doses. This page keeps it as a report of what people, websites or other media say.

Ginger for Nausea Relief

Nausea Relief — scientific infographic poster

Nausea is ginger's most evidence-backed indication — and the one where ginger directly competes with first-line pharmacology. One randomized trial and two reviews anchor the literature: Vutyavanich's 2001 Thai obstetric trial used 1 g a day, reported as 250 mg four times daily, for nausea and vomiting in pregnancy (where a 2005 review cites the potential for birth defects from conventional antiemetics, although the combination of vitamin B6 and doxylamine is approved for this use). Chaiyakunapruk's 2006 meta-analysis of postoperative nausea and vomiting (PONV) found ginger better than placebo; comparisons with droperidol and metoclopramide are often quoted, but the abstract reports placebo only. Marx's 2013 systematic review of chemotherapy-induced nausea and vomiting (CINV) found mixed results. The proposed unifying mechanism: in laboratory tests, ginger compounds weakly inhibit the serotonin type 3 (5-HT3) receptor, the receptor ondansetron blocks — the same receptor complex, but a different binding site.


Table of Contents

  1. Why Nausea Matters — The Clinical Burden
  2. The 5-HT3 Mechanism (Same Receptor as Ondansetron)
  3. Vutyavanich 2001 — The Pregnancy Foundation Trial
  4. Hyperemesis Gravidarum — The Severe End of Pregnancy Nausea
  5. Chaiyakunapruk 2006 — Postoperative Nausea Meta-Analysis
  6. Marx 2013 — Chemotherapy-Induced Nausea Systematic Review
  7. Motion Sickness — The Original Mowrey 1982 Lancet Trial
  8. Vestibular vs. Chemoreceptor Nausea — Where Ginger Works Best
  9. Doses Used in Trials and in Practice — Forms, Timing, Routes
  10. Cautions and Contraindications
  11. Key Research Papers
  12. Connections
  13. Featured Videos

Why Nausea Matters — The Clinical Burden

Nausea is the most common symptom in clinical medicine after pain. Roughly 70–80% of pregnant women experience it (with about 1% progressing to hyperemesis gravidarum requiring hospitalization), 30–50% of post-surgical patients develop postoperative nausea/vomiting, and over 70% of patients receiving chemotherapy report nausea despite widespread use of antiemetics (Ryan 2012). Beyond the immediate suffering, untreated nausea drives dehydration, electrolyte derangement, weight loss, treatment non-adherence, and (in chemotherapy patients) outright refusal of further cycles — with measurable impact on cancer survival.

The pharmacologic challenge is that the "perfect" antiemetic does not exist. Ondansetron is highly effective but can cause QT prolongation (U.S. Food and Drug Administration (FDA) warning at higher doses) and constipation, and is unproven for the chronic-low-dose ambulatory use needed in pregnancy. Metoclopramide carries a black-box warning for tardive dyskinesia after chronic use. Prochlorperazine and promethazine cause significant sedation. Scopolamine patches dry every mucous membrane. Cannabinoids are useful but have their own side-effect spectrum and legal complications. Aprepitant is expensive and reserved for highly emetogenic chemotherapy.

Ginger's role is not to displace any of these drugs — it is to occupy the niche where conventional drugs raise concern (pregnancy), poorly tolerated (chronic ambulatory use), or simply additive (CINV adjunctive therapy alongside ondansetron and dexamethasone). The evidence base for that niche has been built up over four decades of trials and reviews, with mixed results in chemotherapy.

Back to Table of Contents

The 5-HT3 Mechanism (Same Receptor as Ondansetron)

The 5-HT3 receptor is a ligand-gated cation channel (not a G-protein-coupled receptor like most other serotonin receptors) expressed at high density in two anatomical locations critical to vomiting:

Ondansetron, granisetron, palonosetron, and tropisetron are all competitive 5-HT3 antagonists; they bind the receptor and block the serotonin signal. They are the dominant first-line agents for chemotherapy-induced nausea precisely because chemotherapy works largely through massive gut-mucosal serotonin release.

Ginger compounds (gingerols and shogaols) inhibit the 5-HT3 receptor in laboratory tests, but from a different site than ondansetron and more weakly. In Abdel-Aziz 2006 (nerve-type cells and guinea-pig gut), all four compounds tested reduced ion flow through the receptor channel and gut contractions, yet none displaced the radioactive antagonist from its binding site, which points to "a modulatory site distinct from the serotonin binding site". Walstab 2013 found non-competitive inhibition of human 5-HT3 receptors at low micromolar levels, in cells and in human gut nerve tissue. Pertz 2011 describes "a weak inhibitory effect". Ondansetron works at low nanomolar levels. A real clinical effect, additive when combined with conventional 5-HT3 antagonists, is the claim built on this. Chemotherapy trials do not all agree: some show ginger plus standard antiemetic prophylaxis outperforming standard prophylaxis alone, and others do not (see the Marx section below).

In guinea-pig gut, ginger compounds also showed weak inhibitory activity at the muscarinic M3 receptor on enteric smooth muscle (the prokinetic effect is discussed in the Digestive Aid & Gastroparesis page) and weak antineurokininergic activity against substance P, whose NK1 receptor is the target of aprepitant. These activities are modest and are proposed to contribute to the broad-spectrum antiemetic profile.

Back to Table of Contents

Vutyavanich 2001 — The Pregnancy Foundation Trial

The Vutyavanich randomized, double-masked, placebo-controlled trial published in Obstetrics & Gynecology in 2001 remains the foundational pregnancy ginger study. Seventy women with nausea and vomiting of pregnancy (NVP), at or before 17 weeks' gestation, were randomized to either ginger 1 g per day, reported as 250 mg powder capsules four times daily, or matching placebo, for 4 days. Outcomes:

The 250 mg four-times-daily dose is widely quoted as the standard for pregnancy nausea and is often attributed to guidelines from the American College of Obstetricians and Gynecologists and the German Society for Gynecology and Obstetrics. Later trials did not all use it: Sripramote 2003 randomized 138 women to ginger 500 mg or vitamin B6 10 mg, three times daily for 3 days, and found no significant difference between them; other follow-up studies used 500 mg twice daily or 350 mg three times daily. The European Medicines Agency page says the reverse for pregnancy: ginger medicines are not for use during pregnancy or breastfeeding, and the use it bases on clinical studies is prevention of motion sickness in adults. The total daily dose of 1–1.5 g of ginger powder covers these trials; the specific dosing interval is described as less critical.

The American College of Obstetricians and Gynecologists Practice Bulletin on NVP recommends ginger as a first-line non-pharmacologic intervention, alongside vitamin B6 (pyridoxine) 10–25 mg every 6–8 hours. The combination of B6 plus doxylamine is the only U.S. Food and Drug Administration-approved drug for NVP; ginger is the only evidence-supported herbal option at the same evidence tier.

One important distinction: the Vutyavanich trial used powdered dried ginger root in capsules, not ginger tea, candied ginger, or ginger ale. The ginger content of commercial ginger ale is essentially negligible (most contain only ginger flavoring extract, not measurable amounts of gingerols), and the sugar load is counterproductive. Crystallized ginger candy contains real ginger but at unpredictable doses. Capsulated standardized powder at 250 mg per cap is the format that matches the trial evidence.

Back to Table of Contents

Hyperemesis Gravidarum — The Severe End of Pregnancy Nausea

Hyperemesis gravidarum (HG) is the severe end of the NVP spectrum — intractable vomiting causing >5% weight loss, ketonuria, electrolyte disturbance, and often requiring hospitalization for intravenous (IV) fluid and antiemetic therapy. It affects roughly 0.3–3% of pregnancies, with substantially higher rates in twin pregnancies, women with a personal or family history of HG, and women with prior hyperemesis (recurrence in later pregnancies ranged from 15 to 81% across five differing studies in a 2020 review, and was 15.2% in a Norwegian registry of 547,238 women).

The first-line pharmacologic approach for HG escalates from doxylamine/B6, to promethazine or dimenhydrinate, to ondansetron, to corticosteroids, to (rarely) total parenteral nutrition. Ginger sits as an adjunct at the lower rungs of this escalation. The 2015 Cochrane update on NVP interventions (41 trials, 5,449 women) found ginger products "may be helpful to women, but the evidence of effectiveness was limited and not consistent", and a lack of high-quality evidence for any particular intervention. It excluded hyperemesis trials by design, so it says nothing about the severe end. A commonly given explanation for thin evidence there is that trial enrollment of severely symptomatic women is logistically difficult (they tend to be hospitalized and unable to tolerate any oral intake).

Practitioners report on the severe end: ginger oil aromatherapy (a few drops on a tissue held near the nose) and ginger lozenges are sometimes tolerated when capsules are not, simply because they bypass the gastric absorption that may be the proximate trigger. Ginger tea brewed thin and consumed in sips may be tolerated for the same reason.

For the very severe end — the women who are hospitalized for HG, on intravenous ondansetron, and still vomiting — ginger is not going to be the rescue therapy. But for the mild-to-moderate first-trimester nausea that affects 70% of pregnancies, the American College of Obstetricians and Gynecologists and most international obstetric societies are described as recommending it as first-line non-pharmacologic therapy.

Back to Table of Contents

Chaiyakunapruk 2006 — Postoperative Nausea Meta-Analysis

Postoperative nausea and vomiting (PONV) affects roughly 30% of all surgical patients and up to 80% in high-risk groups (women, non-smokers, history of motion sickness or prior PONV, opioid use, certain surgery types — laparoscopic, gynecologic, ear-nose-and-throat). PONV is the most common reason for unplanned hospital admission after ambulatory surgery and the single most common patient-cited dissatisfaction with anesthesia care.

Chaiyakunapruk and colleagues published a meta-analysis in 2006 (American Journal of Obstetrics & Gynecology) pooling 5 randomized controlled trials with a total of 363 patients, examining preoperative ginger (typically 1 g of ginger powder given 1 hour before surgery induction). Findings:

A later meta-analysis (Tóth et al. 2018, 10 trials, 918 patients) found a significant reduction in nausea severity (standardized mean difference −0.247), while reductions in how often PONV occurred and in antiemetic use were not statistically significant. A Lee & Chua 2018 meta-analysis is also cited in some accounts; no record of it could be located. The optimal dose appears to be 1 g ginger powder taken approximately 1 hour preoperatively, with no clear additional benefit at higher doses (some evidence for diminishing returns above 2 g).

The contemporary anesthesia practice does not yet routinely incorporate preoperative ginger — the established standard of care is multimodal prophylaxis with 5-HT3 antagonists (ondansetron 4 mg intravenous), dexamethasone (4–8 mg intravenous), and droperidol (low dose, 0.625 mg intravenous) for high-risk patients. Ginger has an emerging role as an additional layer of prophylaxis or as an alternative in patients for whom the standard agents are contraindicated.

Back to Table of Contents

Marx 2013 — Chemotherapy-Induced Nausea Systematic Review

Chemotherapy-induced nausea and vomiting (CINV) is one of the most feared side effects of cancer therapy. Despite the introduction of 5-HT3 antagonists in the 1990s and NK1 antagonists (aprepitant) in the 2000s, nausea continues to be reported by over 70% of patients receiving chemotherapy (Ryan 2012), particularly the delayed phase (24–120 hours post-infusion) where 5-HT3 antagonists are less effective.

The Marx 2013 systematic review in Nutrition Reviews examined 7 randomized or crossover trials of ginger for CINV. It was a review, with no pooled meta-analysis, and its finding was mixed: three studies showed a positive effect, two were in favor with caveats, and two showed no effect. It concludes that "future studies are required" before clinical use can be recommended. The claim often attached to it is that ginger added to standard 5-HT3 antagonist prophylaxis (most commonly ondansetron) significantly reduces acute and delayed nausea, with the largest effect in the delayed phase.

Other studies pull in different directions:

The Ryan et al. 2012 URCC CCOP (University of Rochester Cancer Center Community Clinical Oncology Program) trial deserves specific mention: 744 cancer patients were randomized, and 576 (91% female) were in the final analysis, across four arms (placebo or ginger 0.5 g, 1.0 g, or 1.5 g daily, taken twice daily for 6 days starting 3 days before the first day of chemotherapy). All arms also received standard 5-HT3 antagonist prophylaxis. Results:

The Ryan trial's dosing: 0.5–1.0 g of ginger powder daily, split into two doses, for 6 days in total, counted from 3 days before chemotherapy infusion. Nausea was recorded on Days 1–4, and the benefit was shown for acute nausea on Day 1. The 2017 Society for Integrative Oncology guideline, which covers breast cancer only and cites this trial among three, says ginger "can be considered as an addition to antiemetics" at its Grade C level, from "a limited number of trials", and gives no regimen; its abstract states that "no strong evidence supports the use of ingested dietary supplements" for treatment side effects. The American Society of Clinical Oncology endorsed that guideline in 2018.

Back to Table of Contents

Motion Sickness — The Original Mowrey 1982 Lancet Trial

The modern Western interest in ginger as an antiemetic traces directly to a single 1982 paper in The Lancet by Mowrey and Clayson titled "Motion sickness, ginger, and psychophysics." The authors enrolled 36 undergraduates highly susceptible to motion sickness and randomized them in a triple-arm trial:

Twenty minutes after dosing, subjects were strapped into a tilted rotating chair (a standardized motion sickness provocation rig) and rotated for up to 6 minutes or until they signaled they were about to vomit. The ginger group lasted significantly longer than the placebo group (mean ~5.5 min vs ~3 min) and longer than the dimenhydrinate group. The contrast with dimenhydrinate was particularly striking because the conventional pharmacology of the time held that motion sickness was a primarily vestibular phenomenon — an H1 histamine receptor problem — for which a peripheral gut-acting agent should be useless.

The Mowrey trial has been criticized methodologically (small sample, single trial, possible unblinding by the distinctive ginger taste), and it triggered a generation of follow-up studies with differing results. Stewart 1991 tested powdered ginger (500 or 1,000 mg) and fresh root (1,000 mg) in 28 volunteers, found no protection, and concluded that "ginger does not possess antimotion sickness activity". The European Medicines Agency, by contrast, lists ginger powder for prevention of motion sickness on the basis of clinical studies showing efficacy.

Reported practical use: 250–500 mg ginger powder taken 30–60 minutes before anticipated motion exposure (boat travel, fishing trip, car ride for the susceptible child), repeated every 4 hours as needed. Crystallized ginger chewed during travel is a reasonable continuous-dosing form that doubles as a behavioral distraction. The principal advantage over dimenhydrinate, meclizine, or scopolamine is lack of sedation — useful for adults who need to function during travel or for children where conventional motion-sickness drugs cause paradoxical agitation.

Back to Table of Contents

Vestibular vs. Chemoreceptor Nausea — Where Ginger Works Best

An important pharmacologic clarification helps explain ginger's pattern of benefit: nausea has at least four mechanistically distinct triggers, each acting through different receptor pathways and responding to different drug classes:

  1. Vestibular nausea (motion sickness, vertigo, vestibular migraine) — driven primarily by acetylcholine and histamine at H1 receptors in the vestibular nuclei. First-line drugs: meclizine, dimenhydrinate, scopolamine. Ginger's evidence here is real but modest.
  2. Chemoreceptor trigger zone (CTZ) nausea (chemotherapy, opioids, uremia, electrolyte derangement) — driven by dopamine D2, 5-HT3, and NK1 receptors in the area postrema. First-line drugs: 5-HT3 antagonists, NK1 antagonists, dopamine antagonists. Ginger's evidence here (the CINV literature) is mixed, with 5-HT3 inhibition as the proposed route.
  3. Vagal afferent nausea (gastric distension, mucosal irritation, food poisoning, gastroparesis) — driven by 5-HT3 receptors on vagal terminals in the gut. First-line drugs: 5-HT3 antagonists, prokinetics. Ginger's evidence here is strong, working through both 5-HT3 antagonism and the prokinetic effect discussed in Digestive Aid & Gastroparesis.
  4. Cortical/anticipatory nausea (anxiety-driven, conditioned-response after prior chemotherapy) — driven by higher cortical pathways and limbic input. First-line approach: benzodiazepines (lorazepam), behavioral therapy. Ginger has minimal evidence here.

This framing is offered to explain why ginger's evidence is strongest in pregnancy nausea (largely vagal + CTZ) and postoperative nausea (mixed CTZ + vagal from gas insufflation), mixed in chemotherapy nausea (CTZ), and smaller and less consistent in vestibular and anticipatory nausea. The question it raises is "what receptor pathway is driving the nausea"; ginger is proposed to have its largest effect where 5-HT3 inhibition would help.

Back to Table of Contents

Doses Used in Trials and in Practice — Forms, Timing, Routes

Ginger comes in radically different pharmaceutical forms with very different bioavailability and effect profiles. The amounts below are what the clinical-trial literature used and what people report using.

Timing for specific indications:

Back to Table of Contents

Cautions and Contraindications

Back to Table of Contents

Key Research Papers

  1. Vutyavanich T, Kraisarin T, Ruangsri R (2001). Ginger for nausea and vomiting in pregnancy: randomized, double-masked, placebo-controlled trial. Obstetrics & Gynecology 97(4):577–582. — PubMed PMID: 11275030
  2. Chaiyakunapruk N, Kitikannakorn N, Nathisuwan S et al. (2006). The efficacy of ginger for the prevention of postoperative nausea and vomiting: a meta-analysis. American Journal of Obstetrics & Gynecology 194(1):95–99. — PubMed PMID: 16389016
  3. Marx W, Kiss N, Isenring L (2015). Is ginger beneficial for nausea and vomiting? An update of the literature. Current Opinion in Supportive & Palliative Care 9(2):189–195. — PubMed PMID: 25872115
  4. Marx WM, Teleni L, McCarthy AL et al. (2013). Ginger (Zingiber officinale) and chemotherapy-induced nausea and vomiting: a systematic literature review. Nutrition Reviews 71(4):245–254. — PubMed PMID: 23550785
  5. Ryan JL, Heckler CE, Roscoe JA et al. (2012). Ginger (Zingiber officinale) reduces acute chemotherapy-induced nausea: a URCC CCOP study of 576 patients. Supportive Care in Cancer 20(7):1479–1489. — PubMed PMID: 21818642
  6. Mowrey DB, Clayson DE (1982). Motion sickness, ginger, and psychophysics. The Lancet 1(8273):655–657. — PubMed PMID: 6121968
  7. Lien HC, Sun WM, Chen YH et al. (2003). Effects of ginger on motion sickness and gastric slow-wave dysrhythmias induced by circular vection. American Journal of Physiology — Gastrointestinal & Liver Physiology 284(3):G481–G489. — PubMed: Lien 2003
  8. Pillai AK, Sharma KK, Gupta YK, Bakhshi S (2011). Anti-emetic effect of ginger powder versus placebo as an add-on therapy in children and young adults receiving high emetogenic chemotherapy. Pediatric Blood & Cancer 56(2):234–238. — PubMed PMID: 20842754
  9. Sripramote M, Lekhyananda N (2003). A randomized comparison of ginger and vitamin B6 in the treatment of nausea and vomiting of pregnancy. Journal of the Medical Association of Thailand 86(9):846–853. — PubMed PMID: 14649969
  10. Borrelli F, Capasso R, Aviello G, Pittler MH, Izzo AA (2005). Effectiveness and safety of ginger in the treatment of pregnancy-induced nausea and vomiting. Obstetrics & Gynecology 105(4):849–856. — PubMed PMID: 15802416
  11. Toth B, Lantos T, Hegyi P et al. (2018). Ginger (Zingiber officinale): An alternative for the prevention of postoperative nausea and vomiting. A meta-analysis. Phytomedicine 50:8–18. — PubMed PMID: 30466995
  12. Lete I, Allué J (2016). The Effectiveness of Ginger in the Prevention of Nausea and Vomiting during Pregnancy and Chemotherapy. Integrative Medicine Insights 11:11–17. — PubMed PMID: 27053918
  13. Abdel-Aziz H, Windeck T, Ploch M, Verspohl EJ (2006). Mode of action of gingerols and shogaols on 5-HT3 receptors: binding studies, cation uptake by the receptor channel and contraction of isolated guinea-pig ileum. European Journal of Pharmacology 530(1–2):136–143. — PubMed PMID: 16364290
  14. Walstab J, Krüger D, Stark T et al. (2013). Ginger and its pungent constituents non-competitively inhibit activation of human recombinant and native 5-HT3 receptors of enteric neurons. Neurogastroenterology and Motility 25(5):439–447. — PubMed PMID: 23490018
  15. Pertz HH, Lehmann J, Roth-Ehrang R, Elz S (2011). Effects of ginger constituents on the gastrointestinal tract: role of cholinergic M3 and serotonergic 5-HT3 and 5-HT4 receptors. Planta Medica 77(10):973–978. — PubMed PMID: 21305447
  16. Bossi P, Cortinovis D, Fatigoni S et al. (2017). A randomized, double-blind, placebo-controlled, multicenter study of a ginger extract in the management of chemotherapy-induced nausea and vomiting (CINV) in patients receiving high-dose cisplatin. Annals of Oncology 28(10):2547–2551. — PubMed PMID: 28666335
  17. Crichton M, Marshall S, Marx W, McCarthy AL, Isenring E (2019). Efficacy of Ginger (Zingiber officinale) in Ameliorating Chemotherapy-Induced Nausea and Vomiting and Chemotherapy-Related Outcomes: A Systematic Review Update and Meta-Analysis. Journal of the Academy of Nutrition and Dietetics 119(12):2055–2068. — PubMed PMID: 31519467
  18. Greenlee H, DuPont-Reyes MJ, Balneaves LG et al. (2017). Clinical practice guidelines on the evidence-based use of integrative therapies during and after breast cancer treatment. CA: A Cancer Journal for Clinicians 67(3):194–232. — PubMed PMID: 28436999
  19. Lyman GH, Greenlee H, Bohlke K et al. (2018). Integrative Therapies During and After Breast Cancer Treatment: ASCO Endorsement of the SIO Clinical Practice Guideline. Journal of Clinical Oncology 36(25):2647–2655. — PubMed PMID: 29889605
  20. Matthews A, Haas DM, O'Mathúna DP, Dowswell T (2015). Interventions for nausea and vomiting in early pregnancy. Cochrane Database of Systematic Reviews (9):CD007575. — PubMed PMID: 26348534
  21. Dean CR, Bruin CM, O'Hara ME et al. (2020). The chance of recurrence of hyperemesis gravidarum: A systematic review. European Journal of Obstetrics & Gynecology and Reproductive Biology: X 5:100105. — PubMed PMID: 32021976
  22. Trogstad LI, Stoltenberg C, Magnus P, Skjaerven R, Irgens LM (2005). Recurrence risk in hyperemesis gravidarum. BJOG 112(12):1641–1645. — PubMed PMID: 16305568
  23. Stewart JJ, Wood MJ, Wood CD, Mims ME (1991). Effects of ginger on motion sickness susceptibility and gastric function. Pharmacology 42(2):111–120. — PubMed PMID: 2062873
  24. Heitmann K, Nordeng H, Holst L (2013). Safety of ginger use in pregnancy: results from a large population-based cohort study. European Journal of Clinical Pharmacology 69(2):269–277. — PubMed PMID: 22706624
  25. Tiani KA, Arenaz CM, Spill MK et al. (2024). The Use of Ginger Bioactive Compounds in Pregnancy: An Evidence Scan and Umbrella Review of Existing Meta-Analyses. Advances in Nutrition 15(11):100308. — PubMed PMID: 39343171

PubMed Topic Searches

  1. PubMed: Ginger and pregnancy nausea
  2. PubMed: Ginger and CINV
  3. PubMed: Ginger and PONV
  4. PubMed: Ginger and motion sickness
  5. PubMed: Ginger 5-HT3 mechanism
  6. PubMed: Ginger and hyperemesis gravidarum

Back to Table of Contents

Connections

Back to Table of Contents